PT-141 — 10 mg

Description

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin-receptor agonist (MC3R/MC4R), derived structurally from melanotan II. Bremelanotide was previously approved as a pharmaceutical (marketed as Vyleesi); it is supplied here solely as a lyophilized research chemical.

Research context: In published laboratory and preclinical research, PT-141 has been studied in the context of central melanocortin-receptor (MC3R/MC4R) signaling pathways.

Specifications: Sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH; molecular mass 1025.16 Da; CAS 189691-06-3; purity 99.30% (HPLC); 10 mg lyophilized powder in a sealed vial; storage cool and dry, protected from light.

This product is supplied strictly for in-vitro laboratory research. It is not a drug, food, cosmetic, or dietary supplement, and is not intended for human or animal consumption, medical, veterinary, or household use.